| Literature DB >> 35652310 |
Mark A Stevenson1, Simon M Firestone1, Anita Tolpinrud1, John Stenos2, Anne-Lise Chaber3, Joanne M Devlin1, Catherine Herbert4, An Pas5, Magdalena Dunowska6.
Abstract
Kangaroos are considered to be an important reservoir of Q fever in Australia, although there is limited knowledge on the true prevalence and distribution of coxiellosis in Australian macropod populations. Serological tests serve as useful surveillance tools, but formal test validation is needed to be able to estimate true seroprevalence rates, and few tests have been validated to screen wildlife species for Q fever. In this study, we modified and optimized a phase-specific indirect immunofluorescence assay (IFA) for the detection of IgG antibodies against Coxiella burnetii in macropod sera. The assay was validated against the commercially available ID Screen Q fever indirect multispecies enzyme-linked immunosorbent assay (ELISA) kit (IDVet, Grabels, France) to estimate the diagnostic sensitivity and specificity of each assay, using Bayesian latent class analysis. A direct comparison of the two tests was performed by testing 303 serum samples from 10 macropod populations from the east coast of Australia and New Zealand. The analysis indicated that the IFA had relatively high diagnostic sensitivity (97.6% [95% credible interval [CrI], 88.0 to 99.9]) and diagnostic specificity (98.5% [95% CrI, 94.4 to 99.9]). In comparison, the ELISA had relatively poor diagnostic sensitivity (42.1% [95% CrI, 33.7 to 50.8]) and similar diagnostic specificity (99.2% [95% CrI, 96.4 to 100]) using the cutoff values recommended by the manufacturer. The estimated true seroprevalence of C. burnetii exposure in the macropod populations included in this study ranged from 0% in New Zealand and Victoria, Australia, up to 94.2% in one population from New South Wales, Australia.Entities:
Keywords: Bayesian latent class models; Coxiella burnetii; ELISA; Q fever; enzyme-linked immunosorbent assay; immunofluorescence assay; macropods; sensitivity; specificity; test validation
Mesh:
Substances:
Year: 2022 PMID: 35652310 PMCID: PMC9297833 DOI: 10.1128/jcm.00236-22
Source DB: PubMed Journal: J Clin Microbiol ISSN: 0095-1137 Impact factor: 11.677